Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial

Lung Cancer

Volumn 35, Issue 3, 2002, Pages 315-317

  Koumakis, George ^a   Demiri, Matina ^a   Barbounis, Vassilios ^a   Vassilomanolakis, Michail ^a   Gontikakis, Emmanuel ^a   Pamouksoglou, Philip ^a   Dahabre, Jabrahel ^a   Efremidis, Anna P ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Non small cell lung cancer; Salvage chemotherapy; Weekly paclitaxel

Indexed keywords

PACLITAXEL; PLATINUM;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG TOLERANCE; FEMALE; GRANULOCYTOPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL RATE; TIME FACTORS;

EID: 0036175675     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00441-X     Document Type: Article

References (10)

1. Phase II study of Taxol in patients with non-small cell lung cancer who have failed platinum containing chemotherapy
2. Second line chemotherapy for resistant metastatic non-small cell lung cancer (NSCLC): The role of Taxol
3. Phase II trial of 96 hour paclitaxel infusion in patients with non small cell lung cancer failing previous platinum based or short duration paclitaxel therapy
4. Paclitaxel by 1 hr infusion: An active drug in metastatic non-small cell lung cancer
5. Schedule and dose intensified paclitaxel as weekly 1 hour infusion in pretreated solid tumors: Results of a phase I/II trial
6. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
7. A phase II trial testing gemcitabine as second line chemotherapy for non small cell lung cancer
8. Weekly paclitaxel in patients with advanced lung cancer: Preliminary data from a phase II trial
9. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small cell lung cancer
10. Paclitaxel by 1-hour infusion: An active drug in metastatic non small-cell lung cancer